表紙
市場調查報告書
商品編碼
971182

微生物合同生物製造市場:生物類型(蛋白質/疫苗),微生物表達系統類型(細菌/酵母),操作規模(臨床前/臨床/商業)

Microbial Contract Biomanufacturing Market across Type of Biologic (Proteins, Vaccines and Others), Type of Microbial Expression System Used (Bacterial, Yeast and Others), Scale of Operation (Preclinical / Clinical and Commercial),

出版日期: | 出版商: Roots Analysis | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告調查了合同製的微生物生物製造市場,包括生物類型(蛋白質,疫苗等),使用的微生物表達系統類型(細菌,酵母等)以及經營規模(臨床前/它按臨床/商業,最終用戶和地區提供對市場機會的詳細分析,並提供主要公司的概況和案例研究。

目錄

第1章序言

  • 調查範圍
  • 調查方法
  • 本章概述

第2章執行摘要

第3章簡介

  • 本章概述
  • 生物製藥概述
  • 用於生物製藥生產的表達系統
    • 微生物表達系統
    • 哺乳動物和微生物表達系統
  • 微生物生產過程
    • 自助銀行
    • 上游處理
    • 發酵
    • 下游處理
  • 合同製造概述
  • 需要將微生物生物製造業務外包
  • 微生物生物製造業務總體外包
  • 與微生物生物製造外包相關的收益和風險
  • 選擇CMO合作夥伴時的重要注意事項
  • 摘要

第4章市場情況

  • 本章概述
  • 微生物合同生物製造市場:總體市場情況
    • 分析:成立年份
    • 分析:按公司規模
    • 分析:按總部所在地
    • 分析:按生產設施的位置
    • 分析:按經營規模
    • 分析:按生物學類型
    • 分析:按使用的表達系統類型
    • 分析:按發酵罐類型
    • 分析:按提供的服務類型
    • 分析:通過法規認證/認證
  • 區域分析
    • 分析:北美
    • 分析:歐洲
    • 分析:亞太地區
    • 分析:中東和北非

第5章企業競爭力分析

  • 本章概述
  • 先決條件和關鍵參數
  • 調查方法
  • 競爭力分析
    • 競爭力分析:北美公司
    • 競爭力分析:歐洲公司
    • 競爭力分析:亞太地區公司

第6章公司簡介

  • 本章概述
  • 一家位於北美的微生物合同生物製藥生產商
    • AGC Biologics
    • Aldevron
    • BioVectra
    • Ology Bioservices
  • 歐洲合同微生物生物製藥生產商
    • Eurogentec
    • Northway Biotechpharma
    • Porton Biopharma
  • 一家位於亞太地區的簽約微生物生物製藥製造商
    • EirGenix
    • Etinpro
    • Stelis Biopharma

    第7章最近的合作夥伴關係

    • 本章概述
    • 夥伴關係模型
    • 微生物合同生物製藥製造商:最近的合作夥伴關係
      • 分析:按年份劃分的夥伴關係
      • 分析:按夥伴關係模型的類型
      • 分析:按經營規模
      • 分析:按生物學類型
      • 分析:按優先級字段
      • 分析:按目標治療區域
      • 分析:按地區
      • 最活躍的參與者:按合夥企業數量分析
    • 微生物合同生物製藥生產商:併購
      • 年度合併/收購分析
      • 按獲取類型分析
      • 區域分析
      • 最活躍的參與者:按獲得次數分析
      • 主要增長因素分析

    第8章最近的擴展

    • 本章概述
    • 微生物合同生物製藥生產商:最近的擴張
    • 區域分析

    第9章微生物發酵技術平台

    • 本章概述
    • 微生物發酵常用技術平台
    • 未來平台:通用技術

    第10章總體競爭/增長的評估

    • 本章概述
    • 前提條件/調查方法
    • 相對競爭和增長機會的分析

    第11章決策框架:決策與購買

    • 本章概述
    • 前提條件/參數定義
      • 場景1
      • 場景2
      • 場景3
      • 方案4
    • 摘要

    第12章領先製藥公司在微生物生物製造中的舉措

    • 本章概述
    • 領先製藥公司的微生物生物製造計劃清單
      • 分析:按計劃數量
      • 分析:按年計劃
      • 分析:以主動性為目的
      • 分析:按計劃類型
      • 分析:按發展規模
      • 分析:按藥物分子類型
      • 分析:按使用的微生物表達系統類型分類
      • 分析:按年份列出的計劃和公司
      • 分析:舉措和公司宗旨
      • 區域分析:按投資
    • 主要製藥公司的競爭基準
      • 主要製藥公司摘要

    第13章案例研究:小型與聚合物的比較

    • 本章概述
    • 小分子和高分子量藥物/治療
      • 主要功能比較
      • 微生物生產過程的比較
      • 主要微生物生產挑戰的比較

    第14章市場規模和機會分析

    • 本章概述
    • 主要前提/預測調查方法
    • 總體微生物合同生物製造市場
      • API微生物合同生物製造市場
      • FDF微生物合同生物製造市場
    • 微生物合同生物製造市場:按生物製劑類型分佈
    • 微生物合同生物製造市場:按使用的微生物表達系統類型分佈
    • 微生物合同生物製造市場:按業務規模分佈
    • 微生物合同生物製造市場:按最終用戶分佈
    • 微生物合同生物製造市場:主要地區分佈
      • 北美微生物合同生物製造市場
      • 歐洲微生物合同生物製造市場
    • 亞太微生物合同生物製造市場
    • 中東和北非的微生物合同生物製造市場
    • 拉丁美洲微生物合同生物製造市場

第15章COVID-19大流行對微生物合同的生物製造市場的影響

  • 本章概述
  • 主要公司的當前選擇和恢復計劃
    • KBI Biopharma
    • 龍沙
    • Porton Pharma解決方案
    • 瓦克生物技術
    • 無錫AppTec
  • 微生物合同生物製造對市場機會的影響

第16章SWOT分析

  • 本章概述
  • 優勢
  • 弱點
  • 市場機會
  • 威脅
  • SWOT因素比較

第17章結論

  • 本章概述
  • 要點

第18章採訪記錄

  • 本章概述
  • 氣象生物製藥
  • 生物研究所列表
  • 奧隆
  • Luina Bio
  • 瓦克生物技術

第19章附錄1:匯總數據

目錄

Overview

Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide therapeutics and certain low molecular weight proteins (insulin) and cytokines. Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (with potential application areas in cell and gene therapies, and DNA vaccines), has led to a substantial increase in demand for microbial system-based production. Furthermore, evolutionary advances in manufacturing technologies have resulted in a renewed interest from drug developers in using microbial platforms for the production of complex biologics.

Given the inherent complexities in the development and production of biologics, drug developers have demonstrated the preference to outsource parts of their microbial manufacturing operations, as well. In fact, there has been a rise in the outsourcing activity in relation to microbial fermentation since 2017. Presently, the microbial contract biomanufacturing market features a mix of small, mid-sized and large players, offering end-to-end solutions, ranging from early stage process development to clinical and commercial scale manufacturing and regulatory filing. Despite this being a fairly well-established domain, more than 25 new contract microbial fermentation companies have been established over the last decade. Therefore, in order to remain competitive, CMOs / CDMOs have begun active in acquiring cutting-edge fermentation technologies and investing in the development of the necessary capacity to support the growing demand for novel biologics. It is also worth highlighting that the COVID-19 pandemic is also likely to create significant business opportunities for microbial CMOs as innovator companies are expected to seek support in manufacturing of potential vaccines and other therapeutic modalities. In the long term, we are led to believe that the contract services market catering to this segment of the biopharma industry is anticipated to witness substantial growth in the coming years.

Scope of the Report

The "Microbial Contract Biomanufacturing Market, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any).
  • A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).
  • An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography. Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity.
  • An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
  • A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.
  • A detailed proprietary 2x2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
  • Elaborate profiles of key players that offer contract biomanufacturing services using microbial expression systems across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • An insightful discussion on the impact of COVID-19 outbreak on the overall microbial contract biomanufacturing market, and the key initiatives undertaken by CMOs to combat the challenges posed due to ongoing situation.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbial contract biomanufacturing market. Based on multiple parameters, such as projected growth of the overall microbial biomanufacturing market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of biologic (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] scale of operation (preclinical / clinical and commercial) [D] end user (small, mid-sized and large / very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
  • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
  • Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)
  • Max Rossetto (General Manager, Business Development, Luina Bio)
  • Rob van Dijk (Business Development Manager, WACKER Biotech)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading CMOs with expertise in production of microbial biologics?
  • What are the preferred microbial expression systems used in biologic development and manufacturing?
  • What are the key microbial fermentation technology platforms?
  • Who could be the potential partners for the microbial CMOs?
  • What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
  • What type of expansion initiatives are being carried out by CMOs in this domain?
  • What initiatives are being undertaken by big pharma players in this domain?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?
  • What are the key trends within the microbial contract biomanufacturing market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbial contract biomanufacturing market and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various microbial expression systems used for the development of different types of biologics. Further, it features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the microbial biopharmaceutical industry. In this chapter, we have presented a list of commonly outsourced microbial biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently faced by players engaged in the market.

Chapter 4 provides an overview of the current microbial contract biomanufacturing landscape. It includes information on close to 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the headquarters, number and location of production facilities, type of biologics manufactured, type of microbial expression system used, type of fermenter used, type of services offered, and regulatory accreditations / certifications received (if any).

Chapter 5 provides a detailed 3-D company competitiveness analysis of microbial contract manufacturers based in North America, Europe, Asia Pacific and Middle East, that we came across during our research. The analysis compares companies within each geography on the basis of company experience (considering the experience of contract manufacturer) and company expertise (which takes into account the count of service portfolio, number of biologics manufactured, number of expression system used and scale of operation).

Chapter 6 features detailed profiles of key industry players that offer contract biomanufacturing services using microbial expression systems across different geographies such as, North America, Europe and Asia Pacific and Middle East, at all scales of operation. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, and an informed future outlook.

Chapter 7 features an elaborate analysis of the various partnerships that have been inked amongst players in this domain, in the time period 2016-2020. It provides a brief description on the various types of partnership model (which include manufacturing agreements, product development agreements, process development agreement, service alliances, and others) that have been adopted by stakeholders in this domain. Further, it features the detailed analysis based on the year of agreement, partnership model, scale of operation, type of biologic, focus area of the deal, therapeutic area and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. In addition, it features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, along with the geographical distribution of this activity.

Chapter 8 presents detailed analysis on the various expansion initiatives undertaken by contract biomanufacturers using microbial expression systems, in order to augment their capabilities, over the period 2016-2020. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain.

Chapter 9 provides a list of microbial fermentation technology platforms that are either available in the market. In addition, it features a list of emerging microbial fermentation technologies.

Chapter 10 features a proprietary 2x2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.

Chapter 12 provides a detailed analysis of microbial based biopharmaceuticals manufacturing related initiatives of the big pharma players (shortlisted from the top companies of 2019 by revenues), featuring trends across various parameters, such as number of initiatives, year of initiative and type of initiatives.

Chapter 13 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 14 presents a detailed market forecast analysis, highlighting the likely growth of the microbial contract biomanufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] distribution by type of biologics (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] type by scale of operation (preclinical / clinical and commercial) [D] end user (small, mid-sized and large / very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America).

Chapter 15 highlights the effect of coronavirus outbreak on the global microbial contract biomanufacturing industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs to combat the challenges posed due to ongoing situation. In addition, it includes a brief section on strategies and action plans that biopharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of microbial contract biomanufacturing market, under a SWOT framework.

Chapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbial contract biomanufacturing market, based on the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), Andrea Conforto (Sales and Marketing, Bioservices Director, Olon), Max Rossetto (General Manager, Business Development, Luina Bio) and Rob van Dijk (Business Development Manager, WACKER Biotech).

Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1 Chapter Overview
  • 3.2. Overview of Biopharmaceuticals
  • 3.3. Expression Systems Used for Biopharmaceutical Production
    • 3.3.1. Microbial Expression Systems
      • 3.3.1.1. Bacterial Expression Systems
      • 3.3.1.2. Fungal Expression Systems
      • 3.3.1.3. Yeast Expression Systems
    • 3.3.2. Mammalian versus Microbial Expression Systems
  • 3.4. Microbial Manufacturing Process
    • 3.4.1. Cell Banking
    • 3.4.2. Upstream Processing
    • 3.4.3. Fermentation
    • 3.4.4. Downstream Processing
  • 3.5. Overview of Contract Manufacturing
  • 3.6. Need for Outsourcing Microbial Biomanufacturing Operations
  • 3.7. Commonly Outsourced Microbial Biomanufacturing Operations
  • 3.8. Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing
  • 3.9. Key Considerations while Selecting a CMO Partner
  • 3.10. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Microbial Contract Biomanufacturing Market: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Manufacturing Facility
    • 4.2.5. Analysis by Scale of Operation
    • 4.2.6. Analysis by Type of Biologic
    • 4.2.7. Analysis by Type of Expression System Used
    • 4.2.8. Analysis by Type of Fermenter
    • 4.2.9. Analysis by Type of Service(s) Offered
    • 4.2.10. Analysis by Regulatory Accreditations / Certifications
  • 4.3. Regional Analysis
    • 4.3.1. Analysis by North America
    • 4.3.2. Analysis by Europe
    • 4.3.3. Analysis by Asia Pacific
    • 4.3.4. Analysis by Middle East and North Africa

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.4. Competitiveness Analysis
    • 5.4.1. Competitiveness Analysis: Companies in North America
    • 5.4.2. Competitiveness Analysis: Companies in Europe
    • 5.4.3. Competitiveness Analysis: Companies in Asia Pacific

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Microbial Contract Biomanufacturers based in North America
    • 6.2.1. AGC Biologics
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Service Portfolio
      • 6.2.1.3. Manufacturing Capabilities and Facilities
      • 6.2.1.4. Recent Developments and Future Outlook
    • 6.2.2. Aldevron
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Service Portfolio
      • 6.2.2.3. Manufacturing Capabilities and Facilities
      • 6.2.2.4. Recent Developments and Future Outlook
    • 6.2.3. BioVectra
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Service Portfolio
      • 6.2.3.3. Manufacturing Capabilities and Facilities
      • 6.2.3.4. Recent Developments and Future Outlook
    • 6.2.4. Ology Bioservices
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Service Portfolio
      • 6.2.4.3. Manufacturing Capabilities and Facilities
      • 6.2.4.4. Recent Developments and Future Outlook
  • 6.3. Microbial Contract Biomanufacturers Based in Europe
    • 6.3.1. Eurogentec
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Service Portfolio
      • 6.3.1.3. Manufacturing Capabilities and Facilities
      • 6.3.1.4. Recent Developments and Future Outlook
    • 6.3.2. Northway Biotechpharma
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Service Portfolio
      • 6.3.2.3. Manufacturing Capabilities and Facilities
      • 6.3.2.4. Recent Developments and Future Outlook
    • 6.3.3. Porton Biopharma
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Service Portfolio
      • 6.3.3.3. Manufacturing Capabilities and Facilities
      • 6.3.3.4. Recent Developments and Future Outlook
  • 6.4. Microbial Contract Biomanufacturers Based in Asia Pacific
    • 6.4.1. EirGenix
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Service Portfolio
      • 6.4.1.3. Manufacturing Capabilities and Facilities
      • 6.4.1.4. Recent Developments and Future Outlook
    • 6.4.2. Etinpro
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Service Portfolio
      • 6.4.2.3. Manufacturing Capabilities and Facilities
      • 6.4.2.4. Recent Developments and Future Outlook
    • 6.4.3. Stelis Biopharma
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Service Portfolio
      • 6.4.3.3. Manufacturing Capabilities and Facilities
      • 6.4.3.4. Recent Developments and Future Outlook

    7. RECENT PARTNERSHIPS

    • 7.1. Chapter Overview
    • 7.2. Partnership Models
    • 7.3. Microbial Contract Biomanufacturers: Recent Partnerships
      • 7.3.1. Analysis by Year of Partnerships
      • 7.3.2. Analysis by Type of Partnership Model
      • 7.3.3. Analysis by Scale of Operation
      • 7.3.4. Analysis by Type of Biologic
      • 7.3.5. Analysis by Focus Area
      • 7.3.6. Analysis by Target Therapeutic Area
      • 7.3.7. Analysis by Region
        • 7.3.7.1. Country-Wise Distribution
        • 7.3.7.2. Intercontinental and Intracontinental Agreements
      • 7.3.8. Most Active Players: Analysis by Number of Partnerships
    • 7.4. Microbial Contract Biomanufacturers: Mergers and Acquisitions
      • 7.4.1. Analysis by Year of Merger / Acquisition
      • 7.4.2. Analysis by Type of Acquisition
      • 7.4.3. Regional Analysis
        • 7.4.3.1. Continent-wise Distribution
        • 7.4.3.2. Country-wise Distribution
        • 7.4.3.3. Intercontinental and Intracontinental Deals
      • 7.4.4. Most Active Players: Analysis by Number of Acquisitions
      • 7.4.5. Analysis by Key Value Drivers
        • 7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers

    8. RECENT EXPANSIONS

    • 8.1. Chapter Overview
    • 8.2. Microbial Contract Biomanufacturers: Recent Expansions
      • 8.2.1. Analysis by Year of Expansion
      • 8.2.2. Analysis by Type of Expansion
      • 8.2.3. Analysis by Scale of Operation
      • 8.2.4. Analysis by Type of Biologic
    • 8.3. Geographical Analysis
      • 8.3.1. Continent-wise Distribution

    9. MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS

    • 9.1. Chapter Overview
    • 9.2. Technology Platforms Commonly Used for Microbial Fermentation
    • 9.3. Upcoming Platforms-General Technologies

    10. ASSESSMENT OF RELATIVE COMPETITION AND GROWTH

    • 10.1. Chapter Overview
    • 10.2. Assumptions and Methodology
    • 10.3. Analysis of Relative Competition and Growth Opportunities
      • 10.3.1. Established Biologics in Emerging Region
      • 10.3.2. Established Biologics in Established Region
      • 10.3.3. Emerging Biologics in Emerging Region
      • 10.3.4. Emerging Biologics in Established Region

    11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

    • 11.1. Chapter Overview
    • 11.2. Assumptions and Parameter Definitions
      • 11.2.1. Scenario 1
      • 11.2.2. Scenario 2
      • 11.2.3. Scenario 3
      • 11.2.4. Scenario 4
    • 11.3. Concluding Remarks

    12. BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING

    • 12.1. Chapter Overview
    • 12.2. List of Microbial Biomanufacturing Initiatives of Big Pharma Players
      • 12.2.1. Analysis by Number of Initiatives
      • 12.2.2. Analysis by Year of Initiative
      • 12.2.3. Analysis by Purpose of Initiative
      • 12.2.4. Analysis by Type of Initiative
      • 12.2.5. Analysis by Development Scale
      • 12.2.6. Analysis by Type of Drug Molecule
      • 12.2.7. Analysis by Type of Microbial Expression System Used
      • 12.2.8. Analysis by Year of Initiative and Company
      • 12.2.9. Analysis by Purpose of Initiative and Company
      • 12.2.10. Geographical Analysis by Investment Made
    • 12.3. Competitive Benchmarking of Big Pharma Players
      • 12.3.1. Big Pharma Summary

    13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE

    • 13.1. Chapter Overview
    • 13.2. Small Molecule and Large Molecule Drugs / Therapies
      • 13.2.1. Comparison of Key Characteristics
      • 13.2.2. Comparison of Microbial Manufacturing Processes
        • 13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules
      • 13.2.3. Comparison of Key Microbial Manufacturing Challenges

    14. MARKET SIZING AND OPPORTUNITY ANALYSIS

    • 14.1. Chapter Overview
    • 14.2. Key Assumptions and Forecast Methodology
    • 14.3. Overall Microbial Contract Biomanufacturing Market, 2020-2030
      • 14.3.1. Microbial Contract Biomanufacturing Market for APIs, 2020-2030
      • 14.3.2. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030
    • 14.4. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
    • 14.5. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used
    • 14.6. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation
    • 14.7. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by End User
    • 14.8. Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions
      • 14.8.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030
        • 14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins
        • 14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes
        • 14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones
        • 14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based Drugs
        • 14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics
        • 14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems
        • 14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems
        • 14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
        • 14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations
        • 14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
        • 14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies
        • 14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
        • 14.8.1.14. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
      • 14.8.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030
        • 14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins
        • 14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes
        • 14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones
        • 14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based Drugs
        • 14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics
        • 14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems
        • 14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems
        • 14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems
        • 14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations
        • 14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
        • 14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies
        • 14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
        • 14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
    • 14.8.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030
      • 14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins
      • 14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes
      • 14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones
      • 14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based Drugs
      • 14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics
      • 14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems
      • 14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems
      • 14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems
      • 14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations
      • 14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations
      • 14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
      • 14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies
      • 14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies
    • 14.8.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030
      • 14.8.3.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins
      • 14.8.3.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes
      • 14.8.3.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones
      • 14.8.3.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based Drugs
      • 14.8.3.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics
      • 14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems
      • 14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
      • 14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
      • 14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations
      • 14.8.3.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations
      • 14.8.3.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies
      • 14.8.3.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies
      • 14.8.3.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies
    • 14.8.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030
      • 14.8.3.1. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins
      • 14.8.3.2. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzyme
      • 14.8.3.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormone
      • 14.8.3.4. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based Drug
      • 14.8.3.5. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics
      • 14.8.3.6. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems
      • 14.8.3.7. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems
      • 14.8.3.8. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
      • 14.8.3.9. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations
      • 14.8.3.10. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations
      • 14.8.3.11. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies
      • 14.8.3.12. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies
      • 14.8.3.13. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies

15. IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET

  • 15.1. Chapter Overview
  • 15.2. Current Options and Recuperative Initiatives of Key Players
    • 15.2.1. KBI Biopharma
    • 15.2.2. Lonza
    • 15.2.3. Porton Pharma Solutions
    • 15.2.4. Wacker Biotech
    • 15.2.5. Wuxi AppTec
  • 15.3. Impact on Microbial Contract Biomanufacturing Market Opportunity

16. SWOT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Strengths
  • 16.3. Weaknesses
  • 16.4. Opportunities
  • 16.5. Threats
  • 16.6. Comparison of SWOT Factors

17. CONCLUSION

  • 17.1. Chapter Overview
  • 17.2. Key Takeaways

18. INTERVIEW TRANSCRIPTS

  • 18.1. Chapter Overview
  • 18.2. Meteoric Biopharmaceuticals
    • 18.2.1. Company Snapshot
    • 18.2.2. Interview Transcript: Gaurav Kaushik (Chief Executive Officer and Managing Director)
  • 18.3. List Biological Laboratories
    • 18.3.1. Company Snapshot
    • 18.3.2. Interview Transcript: Debbie Pinkston (Vice President, Sales and Business Development)
  • 18.4. Olon
    • 18.4.1. Company Snapshot
    • 18.4.2. Interview Transcript: Andrea Conforto (Sales and Marketing, Bioservices Director)
  • 18.5. Luina Bio
    • 18.5.1. Company Snapshot
    • 18.5.2. Interview Transcript: Max Rossetto (General Manager, Business Development)
  • 18.6. WACKER Biotech
    • 18.6.1. Company Snapshot
    • 18.6.2. Interview Transcript: Rob van Dijk (Business Development Manager)

19. APPENDIX 1: TABULATED DATA

List Of Figures

  • Figure 3.1. Biopharmaceuticals Expressed in Microbial Expression Systems
  • Figure 3.2. Types of Expression System
  • Figure 3.3. Sequential Stages of the Microbial Manufacturing Process
  • Figure 3.4. Master and Working Cell Bank Systems
  • Figure 3.5. Types of Third-Party Service Providers
  • Figure 3.6. Commonly Outsourced Microbial Contract Biomanufacturing Operations
  • Figure 3.7. Advantages and Disadvantages Associated with Outsourcing Manufacturing
  • Figure 4.1. Microbial Contract Biomanufacturers: Distribution by Year of Establishment
  • Figure 4.2 Microbial Contract Biomanufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Figure 4.3. Microbial Contract Biomanufacturers: Distribution by Company Size
  • Figure 4.4. Microbial Contract Biomanufacturers: Distribution by Location of
  • Figure 4.5. Microbial Contract Biomanufacturers: Distribution by Location of Manufacturing Facilities (Country-Wise)
  • Figure 4.6. Microbial Contract Biomanufacturers: Distribution by Scale of Operation
  • Figure 4.7. Microbial Contract Biomanufacturers: Distribution by Type of Biologics Manufactured
  • Figure 4.8. Microbial Contract Biomanufacturers: Distribution by Type of Expression System Used
  • Figure 4.9. Microbial Contract Biomanufacturers: Distribution by Type of Fermenter Used
  • Figure 4.10. Microbial Contract Biomanufacturers: Distribution by Type of Service(s) Offered
  • Figure 4.11. Microbial Contract Biomanufacturers: Distribution by Regulatory Accreditations / Certifications Obtained
  • Figure 4.12. Regional Capability Analysis: North America
  • Figure 4.13. Regional Capability Analysis: Europe
  • Figure 4.14. Regional Capability Analysis: Asia Pacific and Middle East
  • Figure 5.1. Company Competitiveness Analysis: Microbial Contract Biomanufacturing in North America
  • Figure 5.2. Company Competitiveness Analysis: Microbial Contract Biomanufacturing in Europe
  • Figure 5.3. Company Competitiveness Analysis: Microbial Contract Biomanufacturing in Asia Pacific
  • Figure 6.1. AGC Biologics: Service Portfolio
  • Figure 6.2. Aldevron: Service Portfolio
  • Figure 6.3. BioVectra: Service Portfolio
  • Figure 6.4. Ology Bioservices: Service Portfolio
  • Figure 6.5. Eurogentec: Service Portfolio
  • Figure 6.6. Northway Biotechpharma: Service Portfolio
  • Figure 6.7. Porton Biopharma: Service Portfolio
  • Figure 6.8. EirGenix: Service Portfolio
  • Figure 6.9. Etinpro: Service Portfolio
  • Figure 6.10. Stelis Biopharma: Service Portfolio
  • Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
  • Figure 7.2. Recent Partnerships: Distribution by Type of Partnership
  • Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership
  • Figure 7.4. Recent Partnerships: Distribution by Scale of Operation
  • Figure 7.5. Recent Partnerships: Distribution by Type of Biologic
  • Figure 7.6. Recent Partnerships: Distribution by Focus Area
  • Figure 7.7. Recent Partnerships: Distribution by Target Therapeutic Area
  • Figure 7.8. Recent Partnerships: Country-Wise Distribution
  • Figure 7.9. Recent Partnerships: Intercontinental and Intracontinental Deals
  • Figure 7.10. Recent Partnerships: Most Active Players
  • Figure 7.11. Acquisitions: Distribution by Year of Acquisition
  • Figure 7.12. Acquisitions: Distribution by Type of Acquisition
  • Figure 7.13. Acquisitions: Country-wise Distribution
  • Figure 7.14. Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Figure 7.15. Acquisitions: Key Value Drivers
  • Figure 8.1. Recent Expansions: Cumulative Distribution by Year of Expansion, 2016-2020
  • Figure 8.2. Recent Expansions: Distribution by Type of Expansion
  • Figure 8.3. Recent Expansions: Distribution by Scale of Operation
  • Figure 8.4. Recent Expansions: Distribution by Type of Biologic
  • Figure 8.5. Recent Expansion: Distribution by Geography
  • Figure 10.1. Relative Competition and Growth Opportunities: Analytical Output
  • Figure 10.2. Relative Competition and Growth Opportunities Related to Established
  • Figure 10.3. Relative Competition and Growth Opportunities Related to Established
  • Figure 10.4. Relative Competition and Growth Opportunities Related to Emerging
  • Figure 10.5. Relative Competition and Growth Opportunities Related to Emerging
  • Figure 11.1. Make versus Buy Decision Making Framework
  • Figure 11.2. Make versus Buy Decision Making: Possible Scenarios
  • Figure 12.1. Big Pharma Players: Distribution by Number of Microbial Biomanufacturing Focused Initiatives
  • Figure 12.2. Big Pharma Players: Cumulative Distribution by Year of Initiative
  • Figure 12.3. Big Pharma Players: Distribution by Purpose of Initiative
  • Figure 12.4. Big Pharma Players: Distribution by Type of Initiative
  • Figure 12.5. Big Pharma Players: Distribution by Development Scale
  • Figure 12.6. Big Pharma Players: Distribution by Type of Drug Molecule
  • Figure 12.7. Big Pharma Players: Distribution by Type of Biologic Manufactured
  • Figure 12.8. Big Pharma Players: Distribution by Type of Microbial Expression System Used
  • Figure 12.9. Big Pharma Players: Distribution by Year of Initiative and Company
  • Figure 12.10. Big Pharma Players: Distribution by Purpose of Initiative and Company
  • Figure 12.11. Big Pharma Players: Distribution by Location of Initiative
  • Figure 12.12. Big Pharma Players: Distribution by Location of Initiative and Company
  • Figure 12.13. Harvey Ball Analysis: Big Pharma Summary
  • Figure 13.1. Small Molecules versus Large Molecules: Comparison of Key Characteristics
  • Figure 13.2. Small Molecules versus Large Molecule: Comparison of Manufacturing Process
  • Figure 13.3. Microbial Contract Biomanufacturing: Distribution by Type of Product
  • Figure 13.4. Microbial Contract Biomanufacturing: Distribution by Type of Expression System
  • Figure 14.1 Overall Microbial Contract Biomanufacturing Market, 2020-2030 (USD Billion)
  • Figure 14.2. Microbial Contract Biomanufacturing Market for APIs, 2020-2030 (USD Billion)
  • Figure 14.3. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030 (USD Billion)
  • Figure 14.4. Microbial Contract Biomanufacturing Market: Distribution by Type of Biologic, 2020, 2025 and 2030
  • Figure 14.5. Microbial Contract Biomanufacturing Market: Distribution by Type of Microbial Expression System Used, 2020, 2025 and 2030
  • Figure 14.6. Microbial Contract Biomanufacturing Market: Distribution by Scale of Operation, 2020, 2025 and 2030
  • Figure 14.7. Microbial Contract Biomanufacturing Market: Distribution by Type of End User, 2020, 2025 and 2030
  • Figure 14.8. Microbial Contract Biomanufacturing Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030
  • Figure 14.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030 (USD Billion)
  • Figure 14.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins (USD Billion)
  • Figure 14.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes (USD Billion)
  • Figure 14.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones (USD Billion)
  • Figure 14.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Figure 14.14. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics (USD Billion)
  • Figure 14.15. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Figure 14.16. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Figure 14.17. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Figure 14.18. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 14.19. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 14.20. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 14.21. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 14.22. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 14.23. Microbial Contract Biomanufacturing Market in Europe, 2020-2030 (USD Billion)
  • Figure 14.24. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins (USD Billion)
  • Figure 14.25. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes (USD Billion)
  • Figure 14.26. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones (USD Billion)
  • Figure 14.27. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Figure 14.28. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics (USD Billion)
  • Figure 14.29. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Figure 14.30. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Figure 14.31. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Figure 14.32. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 14.33. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 14.34. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 14.35. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 14.36. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 14.37. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030 (USD Billion)
  • Figure 14.38. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins (USD Billion)
  • Figure 14.39. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes (USD Billion)
  • Figure 14.40. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones (USD Billion)
  • Figure 14.41. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Figure 14.42. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics (USD Billion)
  • Figure 14.43. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Figure 14.44. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Figure 14.45. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Figure 14.46. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 14.47. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 14.48. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 14.49. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 14.50. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 14.51. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Figure 14.52. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
  • Figure 14.53. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes (USD Billion)
  • Figure 14.54. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones (USD Billion)
  • Figure 14.55. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Figure 14.56. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
  • Figure 14.57. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Figure 14.58. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Figure 14.59. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Figure 14.60. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 14.61. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 14.62. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 14.63. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 14.64. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 14.65. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Figure 14.66. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
  • Figure 14.67. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Vaccines (USD Billion)
  • Figure 14.68. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
  • Figure 14.69. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression System (USD Billion)
  • Figure 14.70. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Figure 14.71. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Figure 14.72. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 14.73. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 14.74. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 14.75. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 14.76. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 14.77. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030 (USD Billion)
  • Figure 14.78. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins (USD Billion)
  • Figure 14.79. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzymes (USD Billion)
  • Figure 14.80. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormones (USD Billion)
  • Figure 14.81. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Figure 14.82. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics (USD Billion)
  • Figure 14.83. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Figure 14.84. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Figure 14.85. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Figure 14.86. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 14.87. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 14.88. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 14.89. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 14.90. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 15.1. Microbial Contract Biomanufacturing Market, 2017-2030: COVID-19 Impact
  • Figure 16.1. Microbial Contract Biomanufacturing Market: SWOT Analysis
  • Figure 16.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

  • Table 3.1. Mammalian versus Microbial Expression Systems
  • Table 4.1. List of Microbial Contract Biomanufacturers
  • Table 4.2. Microbial Contract Biomanufacturing: Information on Scale of Operation
  • Table 4.3. Microbial Contract Biomanufacturing: Information on Type of Biologic Manufactured
  • Table 4.4. Microbial Contract Biomanufacturing: Information on Type of Expression System Used
  • Table 4.5. Microbial Contract Biomanufacturing: Information on Type of Fermenter Used
  • Table 4.6. Microbial Contract Biomanufacturing: Information on Type of Service(s) Offered
  • Table 4.7. Microbial Contract Biomanufacturing: Information on Regulatory Accreditations / Certifications Obtained
  • Table 6.1. AGC Biologics: Company Overview
  • Table 6.2. AGC Biologics: Overview of Manufacturing Capabilities
  • Table 6.3. AGC Biologics: Recent Developments and Future Outlook
  • Table 6.4. Aldevron: Company Overview
  • Table 6.5. Aldevron: Overview of Manufacturing Capabilities
  • Table 6.6 Aldevron: Recent Developments and Future Outlook
  • Table 6.7. BioVectra: Company Overview
  • Table 6.8. BioVectra: Overview of Manufacturing Capabilities
  • Table 6.9. BioVectra: Recent Developments and Future Outlook
  • Table 6.10. Ology Bioservices: Company Overview
  • Table 6.11. Ology Bioservices: Overview of Manufacturing Capabilities
  • Table 6.12. Ology Bioservices: Recent Developments and Future Outlook
  • Table 6.13. Eurogentec: Company Overview
  • Table 6.14. Eurogentec: Overview of Manufacturing Capabilities
  • Table 6.15. Northway Biotechpharma: Company Overview
  • Table 6.16. Northway Biotechpharma: Overview of Manufacturing Capabilities
  • Table 6.17. Northway Biotechpharma: Recent Developments and Future Outlook
  • Table 6.18. Porton Biopharma: Company Overview
  • Table 6.19. Porton Biopharma: Overview of Manufacturing Capabilities
  • Table 6.20. EirGenix: Company Overview
  • Table 6.21. EirGenix: Overview of Manufacturing Capabilities
  • Table 6.22. Etinpro: Company Overview
  • Table 6.23. Etinpro: Overview of Manufacturing Capabilities
  • Table 6.24. Stelis Biopharma: Company Overview
  • Table 6.25. Stelis Biopharma: Overview of Manufacturing Capabilities
  • Table 6.26. Stelis Biopharma: Recent Developments and Future Outlook
  • Table 7.1. Microbial Contract Biomanufacturers: List of Partnerships, 2016-2020
  • Table 7.2. Microbial Contract Biomanufacturers: Acquisitions, 2016-2020
  • Table 7.3. Microbial Contract Biomanufacturers: Acquisitions by Key Value Drivers, 2016- 2020
  • Table 8.1. Microbial Contract Biomanufacturers: List of Expansions
  • Table 9.1. List of Technology Platforms for Microbial Manufacturing
  • Table 12.1. Big Pharmaceutical Players: List of Initiatives
  • Table 13.1. List of Microbial Contract Biomanufacturers
  • Table 13.2. Small Molecules and Large Molecules: Comparison of Development Characteristics
  • Table 17.1. Microbial Contract Biomanufacturing Market: Key Takeaways
  • Table 19.1. Microbial Contract Biomanufacturers: Distribution by Year of Establishment
  • Table 19.2. Microbial Contract Biomanufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Table 19.3. Microbial Contract Biomanufacturers: Distribution by Company Size
  • Table 19.4. Microbial Contract Biomanufacturers: Distribution by Distribution by Location of Headquarters (Country-wise)
  • Table 19.5. Microbial Contract Biomanufacturers: Distribution by Location of Manufacturing Facilities (Country-Wise)
  • Table 19.6. Microbial Contract Biomanufacturers: Distribution by Scale of Operation
  • Table 19.7. Microbial Contract Biomanufacturers: Distribution by Type of Biologics Manufactured
  • Table 19.8. Microbial Contract Biomanufacturers: Distribution by Type of Expression System Used
  • Table 19.9. Microbial Contract Biomanufacturers: Distribution by Type of Fermenter Used
  • Table 19.10. Microbial Contract Biomanufacturers: Distribution by Type of Service(s) Offered
  • Table 19.11. Microbial Contract Biomanufacturers: Distribution by Regulatory Accreditations / Certifications Obtained
  • Table 19.12. Recent Partnerships: Cumulative Distribution by Year of Partnership
  • Table 19.13. Recent Partnerships: Distribution by Partnership Model
  • Table 19.14. Recent Partnerships: Year-wise Trend by Type of Partnership
  • Table 19.15. Recent Partnerships: Distribution by Scale of Operation
  • Table 19.16. Recent Partnerships: Distribution by Type of Biologic
  • Table 19.17. Recent Partnerships: Distribution by Focus Area
  • Table 19.18. Recent Partnerships: Distribution by Target Therapeutic Area
  • Table 19.19. Recent Partnerships: Country-Wise Distribution
  • Table 19.20. Recent Partnerships: Intercontinental and Intracontinental Deals
  • Table 19.21. Recent Partnerships: Most Active Players
  • Table 19.22. Acquisitions: Distribution by Year of Acquisition
  • Table 19.23. Acquisitions: Distribution by Type of Acquisition
  • Table 19.24. Acquisitions: Country-wise Distribution
  • Table 19.25. Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Table 19.26. Acquisitions: Key Value Drivers
  • Table 19.27. Recent Expansions: Cumulative Distribution by Year of Expansion, 2016-2020
  • Table 19.28. Recent Expansions: Distribution by Type of Expansion
  • Table 19.29. Recent Expansions: Distribution by Scale of Operation
  • Table 19.30. Recent Expansions: Distribution by Type of Biologic
  • Table 19.31. Recent Expansion: Distribution by Geography
  • Table 19.32. Big Pharma Players: Distribution by Number of Microbial Biopharmaceutical Manufacturing Focused Initiatives
  • Table 19.33. Big Pharma Players: Cumulative Distribution by Year of Initiative
  • Table 19.34. Big Pharma Players: Distribution by Purpose of Initiative
  • Table 19.35. Big Pharma Players: Distribution by Type of Initiative
  • Table 19.36. Big Pharma Players: Distribution by Development Scale
  • Table 19.37. Big Pharma Players: Distribution by Type of Drug Molecule
  • Table 19.38. Big Pharma Players: Distribution by Type of Biologic Manufactured
  • Table 19.39. Big Pharma Players: Distribution by Type of Microbial Expression System Used
  • Table 19.40. Big Pharma Players: Distribution by Year of Initiative and Company
  • Table 19.41. Big Pharma Players: Distribution by Purpose of Initiative and Company
  • Table 19.42. Big Pharma Players: Distribution by Location of Initiative
  • Table 19.43. Big Pharma Players: Distribution by Location of Initiative and Company
  • Table 19.44. Microbial Contract Biomanufacturing: Distribution by Type of Product
  • Table 19.45. Microbial Contract Biomanufacturing: Distribution by Type of Expression System Used
  • Table 19.46. Overall Microbial Contract Biomanufacturing Market, 2020-2030 (USD Billion)
  • Table 19.47. Microbial Contract Biomanufacturing Market for APIs, 2020-2030 (USD Billion)
  • Table 19.48. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030 (USD Billion)
  • Table 19.49. Microbial Contract Biomanufacturing Market: Distribution by Type of Biologic, 2020, 2025 and 2030
  • Table 19.50. Microbial Contract Biomanufacturing Market: Distribution by Type of Microbial Expression System Used, 2020, 2025 and 2030
  • Table 19.51. Microbial Contract Biomanufacturing Market: Distribution by Scale of Operation, 2020, 2025 and 2030
  • Table 19.52. Microbial Contract Biomanufacturing Market: Distribution by Type of End User, 2020, 2025 and 2030
  • Table 19.53. Microbial Contract Biomanufacturing Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030
  • Table 19.54. Microbial Contract Biomanufacturing Market in North America, 2020-2030 (USD Billion)
  • Table 19.55. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins (USD Billion)
  • Table 19.56. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes (USD Billion)
  • Table 19.57. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones (USD Billion)
  • Table 19.58. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Table 19.59. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics (USD Billion)
  • Table 19.60. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Table 19.61. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Table 19.62. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Table 19.63. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
  • Table 19.64. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 19.65. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
  • Table 19.66. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Table 19.67. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 19.68. Microbial Contract Biomanufacturing Market in Europe, 2020-2030 (USD Billion)
  • Table 19.69. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins (USD Billion)
  • Table 19.70. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes (USD Billion)
  • Table 19.71. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones (USD Billion)
  • Table 19.72. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Table 19.73. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics (USD Billion)
  • Table 19.74. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Table 19.75. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Table 19.76. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Table 19.77. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
  • Table 19.78. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 19.79. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
  • Table 19.80. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Table 19.81. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 19.82. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030 (USD Billion)
  • Table 19.83. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins (USD Billion)
  • Table 19.84. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes (USD Billion)
  • Table 19.85. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones (USD Billion)
  • Table 19.86. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Table 19.87. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics (USD Billion)
  • Table 19.88. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Table 19.89. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Table 19.90. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Table 19.91. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
  • Table 19.92. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 19.93. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies (USD Billion)
  • Table 19.94. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Table 19.95. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 19.96. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Table 19.97. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
  • Table 19.98. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes (USD Billion)
  • Table 19.99. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones (USD Billion)
  • Table 19.100. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Table 19.101. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
  • Table 19.102. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Table 19.103. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Table 19.104. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Table 19.105. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
  • Table 19.106. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 19.107. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
  • Table 19.108. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Table 19.109. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 19.110. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Table 19.111. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins (USD Billion)
  • Table 19.112. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Vaccines (USD Billion)
  • Table 19.113. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics (USD Billion)
  • Table 19.114. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression System (USD Billion)
  • Table 19.115. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Table 19.116. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Table 19.117. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations (USD Billion)
  • Table 19.118. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 19.119. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies (USD Billion)
  • Table 19.120. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Table 19.121. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 19.122. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030 (USD Billion)
  • Table 19.123. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins (USD Billion)
  • Table 19.124. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzymes (USD Billion)
  • Table 19.125. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormones (USD Billion)
  • Table 19.126. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based drugs (USD Billion)
  • Table 19.127. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics (USD Billion)
  • Table 19.128. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems (USD Billion)
  • Table 19.129. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems (USD Billion)
  • Table 19.130. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems (USD Billion)
  • Table 19.131. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations (USD Billion)
  • Table 19.132. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 19.133. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies (USD Billion)
  • Table 19.134. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Table 19.135. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 19.136. Microbial Contract Biomanufacturing Market, 2017-2030: COVID-19 Impact Informed Scenario (USD Billion)